BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) Financial Statements


BioMarin Pharmaceutical Financial Overview

BioMarin Pharmaceutical's market cap is currently ―. The company's EPS TTM is $0.763; its P/E ratio is 121.70; BioMarin Pharmaceutical is scheduled to report earnings on February 21, 2024, and the estimated EPS forecast is $0.23. See an overview of income statement, balance sheet, and cash flow financials.
Sep 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue$ 581.33M$ 584.70M$ 596.41M$ 537.54M$ 505.34M
Gross Profit$ 456.58M$ 482.82M$ 454.20M$ 410.25M$ 389.06M
EBIT$ 45.45M$ 74.56M$ 60.46M$ -14.53M$ 2.77M
EBITDA$ 70.03M$ 98.45M$ 85.94M$ 10.03M$ 27.58M
Net Income Common Stockholders$ 71.74M$ 56.04M$ 50.85M$ -249.00K$ -6.65M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.13B$ 1.17B$ 1.15B$ 1.29B$ 1.27B
Total Assets$ 6.76B$ 6.56B$ 6.43B$ 6.38B$ 6.26B
Total Debt$ 1.09B$ 1.08B$ 1.08B$ 1.09B$ 1.09B
Net Debt$ -39.86M$ -85.96M$ -68.08M$ -198.14M$ -182.51M
Total Liabilities$ 1.86B$ 1.78B$ 1.77B$ 1.77B$ 1.70B
Stockholders Equity$ 4.90B$ 4.78B$ 4.66B$ 4.60B$ 4.57B
Cash Flow-
Free Cash Flow$ 112.23M$ 47.38M$ -98.75M$ -29.57M$ 121.85M
Operating Cash Flow$ 135.65M$ 70.11M$ -73.98M$ 6.79M$ 158.32M
Investing Cash Flow$ -45.80M$ 29.53M$ -30.01M$ -54.71M$ -23.40M
Financing Cash Flow$ -788.00K$ 11.96M$ -40.74M$ 10.87M$ 7.54M
Currency in USD

BioMarin Pharmaceutical Earnings and Revenue History

BioMarin Pharmaceutical Debt to Assets

BioMarin Pharmaceutical Cash Flow

BioMarin Pharmaceutical Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis